Understanding the role of genetic variability in LRRK2 in Indian population

Genetic variability in LRRK2 has been unequivocally established as a major risk factor for familial and sporadic forms of PD in ethnically diverse populations.

[1]  J. Landers,et al.  The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1 , 2018, Front. Mol. Neurosci..

[2]  Dimitrios Vlachakis,et al.  A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway , 2018, Scientific Reports.

[3]  Sonja W. Scholz,et al.  Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease , 2017, Neurobiology of Aging.

[4]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[5]  Sonja W. Scholz,et al.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases , 2017, Neurobiology of Aging.

[6]  Jean-François Dartigues,et al.  Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing , 2017, Genome Biology.

[7]  A. Reith,et al.  Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors , 2016, The Biochemical journal.

[8]  M. Ueffing,et al.  Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts , 2016, Proceedings of the National Academy of Sciences.

[9]  A. West,et al.  Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers , 2016, Neurology.

[10]  Matthias Mann,et al.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.

[11]  E. Tolosa,et al.  Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. , 2015, Parkinsonism & related disorders.

[12]  M. Nalls,et al.  CHCHD2 and Parkinson's disease , 2015, The Lancet Neurology.

[13]  Jianjun Liu,et al.  CHCHD2 and Parkinson's disease , 2015, The Lancet Neurology.

[14]  Paul J Gilligan,et al.  Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease. , 2015, Current topics in medicinal chemistry.

[15]  Nicholas Eriksson,et al.  NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases , 2015, Neurobiology of Aging.

[16]  S. Tiamkao,et al.  Confirmation of the association between LRRK2 R1628P variant and susceptibility to Parkinson's disease in the Thai population. , 2014, Parkinsonism & related disorders.

[17]  Jing Yi Chua,et al.  LRRK2 G2385R and R1628P Mutations Are Associated with an Increased Risk of Parkinson's Disease in the Malaysian Population , 2014, BioMed research international.

[18]  J. Gan,et al.  The association between the LRRK2 G2385R variant and the risk of Parkinson’s disease: a meta-analysis based on 23 case–control studies , 2014, Neurological Sciences.

[19]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[20]  Matthew D. Wilkerson,et al.  ABRA: improved coding indel detection via assembly-based realignment , 2014, Bioinform..

[21]  Ira M. Hall,et al.  SAMBLASTER: fast duplicate marking and structural variant read extraction , 2014, Bioinform..

[22]  T. Wong,et al.  Analysis of non-synonymous-coding variants of Parkinson's disease-related pathogenic and susceptibility genes in East Asian populations. , 2014, Human molecular genetics.

[23]  D. Maraganore,et al.  Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium , 2013, Movement disorders : official journal of the Movement Disorder Society.

[24]  Y. Teo,et al.  Patterns of Linkage Disequilibrium of LRRK2 across Different Races: Implications for Genetic Association Studies , 2013, PloS one.

[25]  Gautami Das,et al.  Movement disorders: Indian scenario: a clinico-genetic review. , 2013, Neurology India.

[26]  J. Quinn,et al.  Common variation in the LRRK2 gene is a risk factor for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[27]  A. Ramesh,et al.  The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients. , 2012, Parkinsonism & related disorders.

[28]  Pablo Cingolani,et al.  Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift , 2012, Front. Gene..

[29]  J. Ioannidis,et al.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.

[30]  A. Kishore,et al.  LRRK2 G2019S mutation does not contribute to Parkinson's disease in South India. , 2011, Neurology India.

[31]  D. Baker,et al.  Role of conformational sampling in computing mutation‐induced changes in protein structure and stability , 2011, Proteins.

[32]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[33]  Susan S. Taylor,et al.  Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.

[34]  V. Rao,et al.  Absence of commonly reported leucine-rich repeat kinase 2 mutations in Eastern Indian Parkinson's disease patients. , 2010, Genetic testing and molecular biomarkers.

[35]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[36]  M. Ueffing,et al.  Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. , 2010, Journal of proteome research.

[37]  Vasanti S. Anand,et al.  LRRK2 in Parkinson’s disease: biochemical functions , 2009, The FEBS journal.

[38]  C. Paisán-Ruiz,et al.  LRRK2 gene variation and its contribution to Parkinson disease , 2009, Human mutation.

[39]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[40]  G. Schellenberg,et al.  LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[41]  Yi Zhao,et al.  LRRK2 R1628P increases risk of Parkinson’s disease: replication evidence , 2008, Human Genetics.

[42]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[43]  R. Roepman,et al.  A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes , 2007, Proteomics.

[44]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[45]  P. Barone,et al.  Apoptotic mechanisms in mutant LRRK2-mediated cell death. , 2007, Human molecular genetics.

[46]  T. Gasser,et al.  Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families , 2007, Neuroscience Letters.

[47]  U. Muthane,et al.  Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients , 2006, Neuroscience Letters.

[48]  Keiji Tanaka,et al.  Cdc37 Interacts with the Glycine-Rich Loop of Hsp90 Client Kinases , 2006, Molecular and Cellular Biology.

[49]  R. Marconi,et al.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease , 2006, European Journal of Human Genetics.

[50]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[51]  Wing-Kin Sung,et al.  Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. , 2005, Human molecular genetics.

[52]  Y. Agid,et al.  G2019S LRRK2 mutation in French and North African families with Parkinson's disease , 2005, Annals of neurology.

[53]  A. Kishore,et al.  Mutational screening of the parkin gene among South Indians with early onset Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[54]  M. Farrer,et al.  The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients , 2005, Neuroscience Letters.

[55]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[56]  J. Jankovic,et al.  A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. , 2008, Parkinsonism & related disorders.

[57]  P. Kolatkar,et al.  The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.